Gastrin I (human): Novel Insights into CCK2 Receptor Signaling in Human iPSC-Derived Intestinal Models

Introduction

The study of gastric acid secretion regulation is central to understanding gastrointestinal physiology and the pathogenesis of digestive disorders. Among the molecular mediators in this complex system, Gastrin I (human) (CAS 10047-33-3) stands out as a pivotal endogenous peptide that orchestrates gastric acid secretion via targeted activation of the cholecystokinin B (CCK2) receptor. While previous research has extensively characterized the role of Gastrin I in traditional in vitro systems, the integration of this peptide into advanced human in vitro models—particularly those derived from human induced pluripotent stem cells (hiPSCs)—offers unprecedented opportunities for both basic research and translational applications. This article provides a comprehensive, mechanistically deep analysis of Gastrin I (human) as a CCK2 receptor agonist in the context of hiPSC-derived intestinal models, delving into its unique advantages for receptor-mediated signal transduction and proton pump activation studies. We contrast this approach with alternative methodologies and build upon, yet distinctly expand, the current literature.

Gastrin I (human): Structure, Biochemical Properties, and Research Utility

Gastrin I (human) is a regulatory peptide with a molecular weight of 2098.22 Da, supplied as a high-purity (≥98%) lyophilized solid. Its biochemical properties—insolubility in water and ethanol, and solubility in DMSO at ≥21 mg/mL—facilitate controlled, reproducible applications in in vitro research. The peptide's primary action lies in stimulating gastric acid secretion by binding to CCK2 receptors on gastric parietal cells, thereby activating intracellular signaling cascades that modulate the activity of the H⁺/K⁺-ATPase (proton pump). This direct link between ligand-receptor interaction and proton pump activation underpins its value in gastric acid secretion pathway research and gastrointestinal physiology studies.

Mechanism of Action: CCK2 Receptor Agonism and Proton Pump Activation

CCK2 Receptor Signaling Cascade

Upon administration, Gastrin I (human) selectively binds to the CCK2 receptor—a G protein-coupled receptor (GPCR) abundantly expressed on gastric parietal cells and certain enteroendocrine cell populations. This receptor-ligand interaction triggers a well-characterized cascade involving phospholipase C activation, inositol trisphosphate (IP₃) generation, and subsequent intracellular Ca²⁺ mobilization. The rise in cytosolic Ca²⁺ is instrumental in activating the proton pump, leading to increased secretion of hydrochloric acid into the gastric lumen.

This tightly regulated process not only underpins normal digestive function but also serves as a critical target for therapeutic intervention in disorders such as Zollinger-Ellison syndrome, peptic ulcer disease, and certain forms of gastric cancer. The precise recapitulation of CCK2 receptor signaling using a high-purity human Gastrin I peptide is therefore invaluable for dissecting the molecular underpinnings of these pathologies.

Receptor-Mediated Signal Transduction in Advanced In Vitro Systems

Traditional cell lines and animal models, while informative, often fail to fully capture the nuances of human gastric physiology. The emergence of hiPSC-derived organoid and monolayer systems now enables researchers to model human-specific signaling events with unprecedented fidelity. In these systems, Gastrin I (human) acts as a gastric acid secretion regulator and a precise probe for studying receptor-mediated signal transduction, including downstream events such as gene expression modulation, cell proliferation, and acid secretion dynamics. This approach has been further validated by quality control using HPLC and mass spectrometry, confirming the peptide's suitability for high-resolution mechanistic studies.

Integration with hiPSC-Derived Intestinal Organoids: A New Era in Translational Gastrointestinal Research

Advanced Human In Vitro Models for GI Physiology

Recent breakthroughs in stem cell biology have enabled the generation of three-dimensional intestinal organoids and two-dimensional epithelial monolayers from hiPSCs. These models, as detailed in a recent seminal study by Saito et al. (2025), recapitulate the cellular diversity and functional properties of the human intestine, including the presence of mature enterocytes and functional enteroendocrine cells. Unlike conventional animal models or immortalized cell lines, hiPSC-derived organoids retain human-specific metabolic enzyme expression and transporter activity, making them ideal for both pharmacokinetic and pathophysiological studies.

Exploiting Gastrin I (human) for Functional Interrogation

Integrating Gastrin I (human) into these organoid and monolayer systems enables researchers to precisely activate CCK2 receptor signaling within a human-relevant context. This allows for:

• Dynamic measurement of proton pump activation and acid secretion in response to physiologic and pharmacologic stimuli.
• Elucidation of downstream signaling networks unique to human gastric and intestinal epithelial cells.
• Modeling of GI disorders—such as hypergastrinemia or hypochlorhydria—under controlled experimental conditions.
• Assessment of drug efficacy and interaction with the gastric acid secretion pathway, relevant for both preclinical and translational research.

This approach builds directly upon the organoid differentiation protocols described by Saito et al., who demonstrated that hiPSC-derived intestinal organoids exhibit mature transporter and metabolic enzyme profiles, thus providing a robust platform for functional studies (see reference).

Comparative Analysis: Gastrin I (human) versus Alternative Approaches

Limitations of Conventional Models

Historically, studies of gastric acid secretion utilized animal models (such as rodents) or transformed cell lines (e.g., Caco-2). While informative, these systems are limited by species-specific differences and aberrant expression of key enzymes or receptors (Saito et al., 2025). For example, Caco-2 cells underexpress CYP3A4 and lack the full complement of human enteroendocrine signaling pathways, leading to misleading results in pharmacological studies.

Advantages of Human Gastrin I Peptide in hiPSC-Derived Systems

By contrast, the use of human Gastrin I peptide in hiPSC-derived models yields several advantages:

• Species Authenticity: Recapitulates human-specific CCK2 receptor signaling and proton pump activation.
• Reproducibility: High purity and strict quality control ensure consistent biological responses.
• Experimental Flexibility: Solubility in DMSO enables precise dosing and compatibility with standard in vitro workflows.
• Translational Relevance: Facilitates direct modeling of human GI disorders, drug metabolism, and therapy response.

These strengths distinguish the approach presented here from prior work such as "Gastrin I (human): Advancing Proton Pump Activation in In...", which primarily focused on mechanistic use in proton pump activation and receptor-mediated signal transduction but did not delve deeply into integration with hiPSC-derived organoids or the translational implications therein.

Distinctive Applications: Beyond Traditional GI Disorder Research

Precision Pharmacology and Drug Screening

The combination of Gastrin I (human) with hiPSC-derived GI models unlocks new possibilities for drug discovery and personalized medicine. Researchers can:

• Model patient-specific responses to CCK2 receptor agonists and antagonists.
• Screen for off-target effects of candidate compounds on gastric acid secretion pathways.
• Investigate gene-environment interactions by introducing genetic variants into hiPSCs and assessing downstream signaling in response to Gastrin I stimulation.

This approach moves beyond the scope of previous articles such as "Gastrin I (human): Precision Modeling of Gastric Acid Reg...", which examined mechanistic insights in hiPSC-derived organoids but did not emphasize the translational and pharmacological potential of this platform for precision medicine applications.

Modeling Rare and Complex GI Disorders

One of the most promising frontiers enabled by this methodology is the in vitro modeling of rare or complex gastrointestinal diseases. By leveraging patient-derived hiPSCs, researchers can generate organoids that faithfully recapitulate disease-specific mutations or phenotypes. Stimulation with highly pure Gastrin I (human) allows for the interrogation of aberrant CCK2 receptor signaling and its contribution to disease progression, paving the way for targeted therapeutic strategies.

Practical Considerations for Experimental Success

To maximize the utility of Gastrin I (human) in advanced in vitro systems, researchers should consider the following technical recommendations:

• Preparation: Dissolve in DMSO at concentrations of ≥21 mg/mL. Avoid water and ethanol to prevent insolubility.
• Storage: Store the lyophilized solid desiccated at -20°C for optimal stability. Use freshly prepared solutions promptly; long-term storage of solutions is not recommended.
• Quality Assurance: Verify peptide integrity and purity prior to use; the product is confirmed at ≥98% purity via HPLC and mass spectrometry.
• Experimental Controls: Include vehicle controls and, where possible, use isogenic hiPSC lines to control for genetic background.

Content Hierarchy and Value: Building on and Expanding Current Literature

Whereas previous articles have highlighted the mechanistic or modeling advances enabled by human Gastrin I peptide, this article provides a unifying perspective that situates these advances within the context of hiPSC-derived organoid technology and translational research. For example, "Gastrin I (human): Advancing Gastric Acid Secretion Pathw..." emphasized the peptide's role in activating CCK2 receptor signaling in organoid models, but did not explore the broader implications for drug screening, personalized medicine, and rare disease modeling offered by the integration with hiPSC technologies. Similarly, "Gastrin I (human): Enabling Advanced GI Physiology Modeli..." discussed applications in gastrointestinal disorder research, whereas this article extends to discuss precision pharmacology and complex disease modeling.

Conclusion and Future Outlook

The integration of Gastrin I (human) as a precise CCK2 receptor agonist in hiPSC-derived intestinal models marks a paradigm shift in gastrointestinal physiology studies. This approach enables detailed dissection of receptor-mediated signal transduction and proton pump activation in a human-relevant context, with direct implications for gastric acid secretion pathway research, drug discovery, and personalized medicine. As stem cell and organoid technologies continue to evolve, the demand for high-quality, reproducible reagents like Gastrin I (human) will only increase. Future research will likely expand into multi-omics analyses, high-throughput screening, and the modeling of increasingly complex GI disorders, further cementing the centrality of this peptide in cutting-edge translational science.

For researchers seeking to advance the frontier of gastrointestinal physiology, Gastrin I (human) (B5358) offers a validated, robust tool for interrogating human-specific CCK2 receptor signaling—and, ultimately, for translating basic research into clinical innovation.